Published in Aviat Space Environ Med on March 01, 1996
Chapter 4. European guidelines for the management of chronic nonspecific low back pain. Eur Spine J (2006) 8.12
Gas chromatography of bacterial whole cell methanolysates; V. Fatty acid composition of Neisseriae and Moraxellae. Acta Pathol Microbiol Scand B Microbiol Immunol (1974) 2.55
Pharmacokinetics of tissue penetration of antibiotics. Rev Infect Dis (1981) 2.54
Pharmacokinetics of mezlocillin in healthy volunteers. Antimicrob Agents Chemother (1978) 2.38
A scoring system for subjective health complaints (SHC). Scand J Public Health (1999) 1.86
Musculoskeletal pain: concepts of disease, illness, and sickness certification in health professionals in Norway. Scand J Rheumatol (1996) 1.78
Psychobiological mechanisms of socioeconomic differences in health. Soc Sci Med (2004) 1.72
Low vagal activity as mediating mechanism for the relationship between personality factors and gastric symptoms in functional dyspepsia. Psychosom Med (1994) 1.67
Crystalluria and ciprofloxacin, influence of urinary pH and hydration. Chemotherapy (1986) 1.66
Pharmacokinetics of bacampicillin compared with those of ampicillin, pivampicillin, and amoxycillin. Antimicrob Agents Chemother (1978) 1.56
Health complaints and job stress in Norwegian physicians: the use of an overlapping questionnaire design. Soc Sci Med (1997) 1.56
Epidemiological markers for Pseudomonas aeruginosa. 6. Relationship between concomitant non-mucoid and mucoid strains from the respiratory tract in cystic fibrosis. Acta Pathol Microbiol Scand Suppl (1975) 1.53
Imipenem/cilastatin, an alternative treatment of pseudomonas infection in cystic fibrosis. J Antimicrob Chemother (1988) 1.48
Electron microscopical and serological characteristics associated with colony type in Moraxella nonliquefaciens. Acta Pathol Microbiol Scand B Microbiol Immunol (1970) 1.47
Five-year follow-up study of a controlled clinical trial using light mobilization and an informative approach to low back pain. Spine (Phila Pa 1976) (1998) 1.45
Gas chromatography of bacterial whole cell methanolysates. VII. Fatty acid composition of Acinetobacter in relation to the taxonomy of Neisseriaceae. Acta Pathol Microbiol Scand Suppl (1975) 1.44
Evaluation of disinfectant inactivators. Acta Pathol Microbiol Scand B Microbiol Immunol (1972) 1.42
Kinetics of tissue penetration. Are high plasma peak concentrations or sustained levels preferable for effective antibiotic therapy? Scand J Infect Dis Suppl (1978) 1.40
Mezlocillin pharmacokinetics in patients with normal and impaired renal functions. Antimicrob Agents Chemother (1979) 1.40
Human pharmacokinetics of a sulfamethoxazole-trimethoprim combination. Acta Med Scand (1972) 1.38
Pharmacokinetics of the antibacterial combination sulfamethoxazole plus trimethoprim in patients with normal or impaired kidney function. Antibiot Chemother (1971) (1974) 1.37
Transintestinal elimination of ciprofloxacin. Chemotherapy (1990) 1.36
Psychological factors and somatic symptoms in functional dyspepsia. A comparison with duodenal ulcer and healthy controls. J Psychosom Res (1994) 1.35
Pharmacokinetic comparison of oral bacampicillin and parenteral ampicillin. Antimicrob Agents Chemother (1978) 1.34
Ofloxacin: serum and skin blister fluid pharmacokinetics in the fasting and non-fasting state. J Antimicrob Chemother (1986) 1.34
DNA base composition of Gram-positive cocci. J Gen Microbiol (1971) 1.33
Pharmacokinetics of ciprofloxacin: intravenous and increasing oral doses. Am J Med (1987) 1.32
Does early intervention with a light mobilization program reduce long-term sick leave for low back pain? Spine (Phila Pa 1976) (2000) 1.32
Influence of food and hepatobiliary disease on the excretion of josamycin. Pharmacology (1972) 1.30
Microbiological assay of josamycin. Acta Pathol Microbiol Scand B Microbiol Immunol (1972) 1.30
Overview of acylureidopenicillin pharmacokinetics. Scand J Infect Dis Suppl (1981) 1.28
Thoroughly modern worries: the relationship of worries about modernity to reported symptoms, health and medical care utilization. J Psychosom Res (2001) 1.25
Chlamydia trachomatis as a cause of acute perihepatitis associated with pelvic inflammatory disease. Br J Vener Dis (1981) 1.25
Pharmacokinetics of ciprofloxacin and effect of repeated dosage on salivary and fecal microflora. Antimicrob Agents Chemother (1986) 1.20
Typing of Pseudomonas aeruginosa by pyocine production. Acta Pathol Microbiol Scand (1968) 1.20
Gas chromatography of bacterial whole cell methanolysates; VI. Fatty acid composition of strains within Micrococcaceae;. Acta Pathol Microbiol Scand B Microbiol Immunol (1974) 1.19
Subjective health complaints, sensitization, and sustained cognitive activation (stress). J Psychosom Res (2004) 1.19
Comparison between the pharmacokinetic properties of mezlocillin when given intravenously as a bolus injection or as an infusion. Arzneimittelforschung (1979) 1.19
Pelvic inflammatory disease: etiologic studies with emphasis on chlamydial infection. Obstet Gynecol (1982) 1.19
Dose dependence of piperacillin pharmacokinetics. Chemotherapy (1982) 1.18
Extravascular penetration of highly protein-bound flucloxacillin. Antimicrob Agents Chemother (1986) 1.17
Pharmacokinetics of ciprofloxacin after intravenous and increasing oral doses. Eur J Clin Microbiol (1986) 1.16
A model for life changes and illness research. Cross-cultural data from the Norwegian Navy. Arch Gen Psychiatry (1974) 1.16
Temocillin in peripheral lymph. J Antimicrob Chemother (1983) 1.14
Ground penetrating radar surveys to locate 1918 Spanish flu victims in permafrost. J Forensic Sci (2000) 1.14
Life events and stress in patients with functional dyspepsia compared with patients with duodenal ulcer and healthy controls. Scand J Gastroenterol (1995) 1.14
Renal excretion of gentamycin in chronic pyelonephritis. Acta Med Scand (1972) 1.13
Pharmacokinetics of beta-lactam antibiotics. Scand J Infect Dis Suppl (1984) 1.12
Reisolation of Micrococcus mucilaginosus Migula 1900. Acta Pathol Microbiol Scand B Microbiol Immunol (1970) 1.09
Penicillins. Antibiot Chemother (1971) (1978) 1.06
Demonstration of extracellular proteolytic enzymes from Legionella species strains by using synthetic chromogenic peptide substrates. Acta Pathol Microbiol Immunol Scand B (1982) 1.06
Epidemiological markers for Pseudomonas aeruginosa. 1. Serogrouping, pyocine typing--and their interrelations. Acta Pathol Microbiol Scand B Microbiol Immunol (1973) 1.05
Assay of cefotaxime by high-pressure-liquid chromatography. Chemotherapy (1981) 1.05
Development of sulphonamide-trimethoprim combinations for urinary tract infections. Part I: Comparison of the antibacterial effect of sulphonamides alone and in combination with trimethoprim. Infection (1979) 1.02
A method for studying responses and habituation to odors in rats. Behav Neural Biol (1982) 1.02
Pharmacokinetics of azlocillin in children with cystic fibrosis. Arzneimittelforschung (1979) 1.01
Effect of norfloxacin on human oropharyngeal and colonic microflora and multiple-dose pharmacokinetics. Scand J Infect Dis (1987) 1.00
Production and characterization of monoclonal antibodies to toxic shock syndrome toxin 1 and use of a monoclonal antibody in a rapid, one-step enzyme-linked immunosorbent assay for detection of picogram quantities of toxic shock syndrome toxin 1. J Clin Microbiol (1987) 1.00
Comparison of numerical procedures for grouping pseudomonas bacteriophages according to lytic spectra. Acta Pathol Microbiol Scand B Microbiol Immunol (1972) 0.99
The CODE: a revised battery for coping and defense and its relations to subjective health. Scand J Psychol (1997) 0.99
Biological availability and in vitro release from oral oxytetracycline and tetracycline preparations. Acta Pharmacol Toxicol (Copenh) (1973) 0.99
The effect of sleep deprivation and recovery sleep on plasma corticosterone in the rat. Neurosci Lett (1983) 0.98
Outer membrane proteins and plasmids in different Yersinia enterocolitica serogroups isolated from man and animals. Acta Pathol Microbiol Immunol Scand B (1985) 0.98
Pharmacokinetics of bacampicillin and bacmecillinam in plasma and peripheral lymph. Lymphology (1979) 0.98
Multimodal cognitive behavioral treatment of patients sicklisted for musculoskeletal pain: a randomized controlled study. Scand J Rheumatol (1998) 0.97
Pharmacokinetics of metronidazole in patients with enteric disease compared to normal volunteers. Chemotherapy (1981) 0.97
Legionnaires' disease combined with erythema multiforme in a 3-year-old boy. Acta Paediatr Scand (1981) 0.97
What are the real problems for patients with functional dyspepsia? Scand J Gastroenterol (1995) 0.96
Bacterial isolates in cholecystitis and cholelithiasis. Scand J Gastroenterol (1979) 0.95
Susceptibility testing of Haemophilus influenzae--an international collaborative study in quality assessment. J Antimicrob Chemother (1996) 0.95
Azlocillin in respiratory tract infections with Pseudomonas aeruginosa in children with cystic fibrosis. Chemotherapy (1980) 0.95
Additional heart rate--an indicator of psychological activation. Aerosp Med (1974) 0.94
Improving subjective health at the worksite: a randomized controlled trial of stress management training, physical exercise and an integrated health programme. Occup Med (Lond) (2002) 0.94
Distribution to human peripheral lymph of amoxycillin and of ampicillin from the oral prodrug bacampicillin. J Antimicrob Chemother (1983) 0.93
Kidney transport in man of sulfamethoxazole and trimethoprim. Chemotherapy (1972) 0.93
Antitubercular action of disinfectants. J Appl Bacteriol (1971) 0.93
Cross-over study of penicillin pharmacokinetics after intravenous infusions. Chemotherapy (1974) 0.93
Stress, control, and coping in elite athletes. Scand J Med Sci Sports (1998) 0.91
Development of sulphonamide-trimethoprim combinations for urinary tract infections. Part 3: Pharmacokinetic characterization of sulphadiazine and sulphamethoxazole given with trimethoprim. Infection (1979) 0.91
The time dimension in stress responses: relevance for survival and health. Psychiatry Res (1999) 0.90
Vaginal disinfection with chlorhexidine during childbirth. Int J Antimicrob Agents (1999) 0.89
Dose-related pharmacokinetics after oral administration of a new formulation of erythromycin base. Br J Clin Pharmacol (1982) 0.89
Penetration of erythromycin into human peripheral lymph. J Antimicrob Chemother (1982) 0.89
Pharmacokinetics of metronidazole in healthy adult volunteers after tablets and suppositories. Chemotherapy (1980) 0.89
Comparative pharmacokinetics of cefazolin, cephalothin, cephacetril, and cephapirine after intravenous administration. Chemotherapy (1977) 0.89
Impact of ticarcillin/clavulanate on the intestinal microflora. J Antimicrob Chemother (1989) 0.89
Human pharmacokinetics of cephalexin. Pharmacology (1970) 0.89
Physical exercise in women with intractable epilepsy. Epilepsia (1995) 0.89
Azlocillin with and without an aminoglycoside against respiratory tract infections in children with cystic fibrosis. Scand J Infect Dis Suppl (1981) 0.87
Transintestinal elimination of ciprofloxacin. Diagn Microbiol Infect Dis (1990) 0.87
Kidney transport of cefazolin in normal and impaired renal function. J Antimicrob Chemother (1977) 0.87
Penetration of ciprofloxacin and metabolites into human lung, bronchial and pleural tissue after 250 and 500 mg oral ciprofloxacin. Chemotherapy (1991) 0.87
Pharmacokinetics of netilmicin in children with and without cystic fibrosis. Antimicrob Agents Chemother (1981) 0.87
Patients with low back pain not returning to work. A 12-month follow-up study. Spine (Phila Pa 1976) (1998) 0.87
Penetration of cefotaxime and desacetylcefotaxime into skin blister fluid. J Antimicrob Chemother (1982) 0.86
Epidemiological markers for pseudomonas aeruginosa. Acta Pathol Microbiol Scand B (1975) 0.86
Short term chemotherapeutic prophylaxis in gastrointestinal operations. Surg Gynecol Obstet (1980) 0.86
Psychotherapy in functional dyspepsia. J Psychosom Res (1994) 0.86
In vitro activity of antifungal agents against yeast species. Chemotherapy (1983) 0.86
Pharmacokinetics of metronidazole and its metabolites in reduced renal function. Chemotherapy (1986) 0.85